151 related articles for article (PubMed ID: 38188613)
61. Expression of ALDH1 and TGFβ2 in benign and malignant breast tumors and their prognostic implications.
Zheng R; Wang J; Wu Q; Wang Z; Ou Y; Ma L; Wang M; Wang J; Yang Y
Int J Clin Exp Pathol; 2014; 7(7):4173-83. PubMed ID: 25120797
[TBL] [Abstract][Full Text] [Related]
62. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
[TBL] [Abstract][Full Text] [Related]
63. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment.
Resetkova E; Reis-Filho JS; Jain RK; Mehta R; Thorat MA; Nakshatri H; Badve S
Breast Cancer Res Treat; 2010 Aug; 123(1):97-108. PubMed ID: 19911270
[TBL] [Abstract][Full Text] [Related]
64. Cancer stem cell markers in adenocarcinoma of the salivary glands - reliable prognostic markers?
Spiegel JL; Jakob M; Kruizenga M; Freytag S; Bertlich M; Canis M; Ihler F; Haubner F; Kitz J; Weiss BG
Eur Arch Otorhinolaryngol; 2021 Jul; 278(7):2517-2528. PubMed ID: 33009929
[TBL] [Abstract][Full Text] [Related]
65. ALDH1+ stem cells demonstrate more stem cell-like characteristics than CD44
Chen J; Liu S; Su Y; Zhang X
Transl Cancer Res; 2020 Mar; 9(3):1652-1659. PubMed ID: 35117513
[TBL] [Abstract][Full Text] [Related]
66. [Vascular endothelial growth factor promotes cancer stemness of triple-negative breast cancer via MAPK/ERK pathway].
Wang L; Zhao L; Zhang L; Jing X; Zhang Y; Shao S; Zhao X; Luo M
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Oct; 41(10):1484-1491. PubMed ID: 34755663
[TBL] [Abstract][Full Text] [Related]
67. Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma--derived CD44(+)ALDH1(+) cells.
Chen YW; Chen KH; Huang PI; Chen YC; Chiou GY; Lo WL; Tseng LM; Hsu HS; Chang KW; Chiou SH
Mol Cancer Ther; 2010 Nov; 9(11):2879-92. PubMed ID: 21062915
[TBL] [Abstract][Full Text] [Related]
68. Characterization of CD44+ALDH1+Ki-67- Cells in Non-malignant and Neoplastic Lesions of the Breast.
DA Cruz Paula A; Marques O; Sampaio R; Rosa A; Garcia J; Rêma A; DE Fátima Faria M; Silva P; Vizcaíno R; Lopes C
Anticancer Res; 2016 Sep; 36(9):4629-38. PubMed ID: 27630305
[TBL] [Abstract][Full Text] [Related]
69. Clinical implications of Ezrin and CD44 co‑expression in breast cancer.
Ma L; Jiang T
Oncol Rep; 2013 Oct; 30(4):1899-905. PubMed ID: 23900701
[TBL] [Abstract][Full Text] [Related]
70. High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer.
Yeong J; Lim JCT; Lee B; Li H; Chia N; Ong CCH; Lye WK; Putti TC; Dent R; Lim E; Thike AA; Tan PH; Iqbal J
Front Immunol; 2018; 9():1209. PubMed ID: 29899747
[TBL] [Abstract][Full Text] [Related]
71. Expression of Androgen Receptor and Cancer Stem Cell Markers (CD44
Riaz N; Idress R; Habib S; Azam I; Lalani EM
Transl Oncol; 2018 Aug; 11(4):920-929. PubMed ID: 29843115
[TBL] [Abstract][Full Text] [Related]
72. Expression of cancer stem cell markers and their correlation with pathogenesis in vascular tumors.
Lan J; Huang B; Liu R; Ju X; Zhou Y; Jiang J; Liang W; Shen Y; Li F; Pang L
Int J Clin Exp Pathol; 2015; 8(10):12621-33. PubMed ID: 26722452
[TBL] [Abstract][Full Text] [Related]
73. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy.
Shien K; Toyooka S; Ichimura K; Soh J; Furukawa M; Maki Y; Muraoka T; Tanaka N; Ueno T; Asano H; Tsukuda K; Yamane M; Oto T; Kiura K; Miyoshi S
Lung Cancer; 2012 Jul; 77(1):162-7. PubMed ID: 22387005
[TBL] [Abstract][Full Text] [Related]
74. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
[TBL] [Abstract][Full Text] [Related]
75. Breast cancer stem cell markers CD44 and ALDH1A1 in serum: distribution and prognostic value in patients with primary breast cancer.
Kong Y; Lyu N; Wu J; Tang H; Xie X; Yang L; Li X; Wei W; Xie X
J Cancer; 2018; 9(20):3728-3735. PubMed ID: 30405844
[No Abstract] [Full Text] [Related]
76. The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients.
Giatromanolaki A; Sivridis E; Fiska A; Koukourakis MI
Med Oncol; 2011 Sep; 28(3):745-52. PubMed ID: 20405247
[TBL] [Abstract][Full Text] [Related]
77. STAT3 as a promising chemoresistance biomarker associated with the CD44
Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
[TBL] [Abstract][Full Text] [Related]
78. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
[TBL] [Abstract][Full Text] [Related]
79. Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast.
Oon ML; Thike AA; Tan SY; Tan PH
Breast Cancer Res Treat; 2015 Feb; 150(1):31-41. PubMed ID: 25677743
[TBL] [Abstract][Full Text] [Related]
80. Aldehyde Dehydrogenase 1 Expression Predicts Chemoresistance and Poor Clinical Outcomes in Patients with Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemotherapy Prior to Radical Hysterectomy.
Xie Q; Liang J; Rao Q; Xie X; Li R; Liu Y; Zhou H; Han J; Yao T; Lin Z
Ann Surg Oncol; 2016 Jan; 23(1):163-70. PubMed ID: 25916979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
